keyword
MENU ▼
Read by QxMD icon Read
search

Gastric Cáncer Molecular Classification

keyword
https://www.readbyqxmd.com/read/30027089/immunotherapy-in-advanced-gastric-cancer-an-overview-of-the-emerging-strategies
#1
REVIEW
Helena Magalhães, Mário Fontes-Sousa, Manuela Machado
Gastric cancer (GC) remains a public health problem, being the fifth most common cancer worldwide. In the western countries, the majority of patients present with advanced disease. Additionally, 65 to 75% of patients treated with curative intent will relapse and develop systemic disease. In metastatic disease, systemic treatment still represents the state of the art, with less than a year of median overall survival. The new molecular classification of GC was published in 2014, identifying four distinct major subtypes of gastric cancer, and has encouraged the investigation of new and more personalized treatment strategies...
2018: Canadian Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/30018477/biomarkers-of-gastric-cancer-current-topics-and-future-perspective
#2
REVIEW
Tasuku Matsuoka, Masakazu Yashiro
Gastric cancer (GC) is one of the most prevalent malignant types in the world and an aggressive disease with a poor 5-year survival. This cancer is biologically and genetically heterogeneous with a poorly understood carcinogenesis at the molecular level. Although the incidence is declining, the outcome of patients with GC remains dismal. Thus, the detection at an early stage utilizing useful screening approaches, selection of an appropriate treatment plan, and effective monitoring is pivotal to reduce GC mortalities...
July 14, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/30008616/molecular-biomarkers-in-gastro-esophageal-cancer-recent-developments-current-trends-and-future-directions
#3
REVIEW
Francesca Battaglin, Madiha Naseem, Alberto Puccini, Heinz-Josef Lenz
Gastro-esophageal adenocarcinomas (GEA) represent a severe global health burden and despite improvements in the multimodality treatment of these malignancies the prognosis of patients remains poor. HER2 overexpression/amplification has been the first predictive biomarker approved in clinical practice to guide patient selection for targeted treatment with trastuzumab in advanced gastric and gastro-esophageal junction cancers. More recently, immunotherapy has been approved for the treatment of GEA and PD-L1 expression is now a biomarker required for the administration of pembrolizumab in these diseases...
2018: Cancer Cell International
https://www.readbyqxmd.com/read/29896679/gastritis-infection-cancer-sequence-of-epstein-barr-virus-associated-gastric-cancer
#4
Masashi Fukayama, Akiko Kunita, Atsushi Kaneda
Epstein-Barr virus-associated gastric cancer (EBVaGC) is a representative EBV-infected epithelial neoplasm, which is now included as one of the four subtypes of The Cancer Genome Atlas molecular classification of gastric cancer. In this review, we portray a gastritis-infection-cancer sequence of EBVaGC. This virus-associated type of gastric cancer demonstrates clonal growth of EBV-infected epithelial cells within the mucosa of atrophic gastritis. Its core molecular abnormality is the EBV-specific hyper-epigenotype of CpG island promoter methylation, which induces silencing of tumor suppressor genes...
2018: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29882766/proposed-molecular-and-mirna-classification-of-gastric-cancer
#5
REVIEW
Lara Alessandrini, Melissa Manchi, Valli De Re, Riccardo Dolcetti, Vincenzo Canzonieri
Gastric cancer (GC) is a common malignant neoplasm worldwide and one of the main cause of cancer-related deaths. Despite some advances in therapies, long-term survival of patients with advanced disease remains poor. Different types of classification have been used to stratify patients with GC for shaping prognosis and treatment planning. Based on new knowledge of molecular pathways associated with different aspect of GC, new pathogenetic classifications for GC have been and continue to be proposed. These novel classifications create a new paradigm in the definition of cancer biology and allow the identification of relevant GC genomic subsets by using different techniques such as genomic screenings, functional studies and molecular or epigenetic characterization...
June 6, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29844297/immunotherapy-for-gastric-cancer-time-for-a-personalized-approach
#6
REVIEW
Riccardo Dolcetti, Valli De Re, Vincenzo Canzonieri
Over the last decade, our understanding of the mechanisms underlying immune modulation has greatly improved, allowing for the development of multiple therapeutic approaches that are revolutionizing the treatment of cancer. Immunotherapy for gastric cancer (GC) is still in the early phases but is rapidly evolving. Recently, multi-platform molecular analyses of GC have proposed a new classification of this heterogeneous group of tumors, highlighting subset-specific features that may more reliably inform therapeutic choices, including the use of new immunotherapeutic drugs...
May 29, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29843478/clinical-importance-of-epstein%C3%A2-barr-virus-associated-gastric-cancer
#7
REVIEW
Jun Nishikawa, Hisashi Iizasa, Hironori Yoshiyama, Kanami Shimokuri, Yuki Kobayashi, Sho Sasaki, Munetaka Nakamura, Hideo Yanai, Kohei Sakai, Yutaka Suehiro, Takahiro Yamasaki, Isao Sakaida
Epstein⁻Barr virus-associated gastric carcinoma (EBVaGC) is the most common malignancy caused by EBV infection. EBVaGC has definite histological characteristics similar to gastric carcinoma with lymphoid stroma. Clinically, EBVaGC has a significantly low frequency of lymph node metastasis compared with EBV-negative gastric cancer, resulting in a better prognosis. The Cancer Genome Atlas of gastric adenocarcinomas proposed a molecular classification divided into four molecular subtypes: (1) EBVaGC; (2) microsatellite instability; (3) chromosomal instability; and (4) genomically stable tumors...
May 29, 2018: Cancers
https://www.readbyqxmd.com/read/29796937/clinical-impact-of-molecular-classifications-in-gastric-cancer
#8
REVIEW
Daniele Marrelli, Karol Polom, Alessandro Neri, Franco Roviello
Treatment options to gastric cancer (GC) have been changing in recent years from a standard to a tailored approach. Different individualized procedures can range from endoscopic resection, D2 with open or minimally invasive approach, to neo-adjuvant therapy followed by extended surgery. In more advanced stages, a combined approach with the inclusion of intraperitoneal chemo-hyperthermia (HIPEC) may represent a new advanced option. The inclusion of histological type according to Laurén classification in the flowchart of treatment could increase both accuracy and effectiveness of such tailored approach...
June 2018: Updates in Surgery
https://www.readbyqxmd.com/read/29760539/new-therapeutic-options-opened-by-the-molecular-classification-of-gastric-cancer
#9
REVIEW
Mihaela Chivu-Economescu, Lilia Matei, Laura G Necula, Denisa L Dragu, Coralia Bleotu, Carmen C Diaconu
Gastric cancer (GC) is one of the most lethal and aggressive cancers, being the third cause of cancer related death worldwide. Even with radical gastrectomy and the latest generation of molecular chemotherapeutics, the numbers of recurrence and mortality remains high. This is due to its biological heterogeneity based on the interaction between multiple factors, from genomic to environmental factors, diet or infections with various pathogens. Therefore, understanding the molecular characteristics at a genomic level is critical to develop new treatment strategies...
May 14, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29743854/microsatellite-instability-in-colorectal-cancer
#10
REVIEW
Jafar Nouri Nojadeh, Shahin Behrouz Sharif, Ebrahim Sakhinia
Colorectal cancer (CRC) is a heterogeneous disease that is caused by the interaction of genetic and environmental factors. Although it is one of the most common cancers worldwide, CRC would be one of the most curable cancers if it is detected in the early stages. Molecular changes that occur in colorectal cancer may be categorized into three main groups: 1) Chromosomal Instability (CIN), 2) Microsatellite Instability (MSI), and 3) CpG Island Methylator phenotype (CIMP). Microsatellites, also known as Short Tandem Repeats (STRs) are small (1-6 base pairs) repeating stretches of DNA scattered throughout the entire genome and account for approximately 3 % of the human genome...
2018: EXCLI journal
https://www.readbyqxmd.com/read/29721214/distinct-molecular-subtypes-of-gastric-cancer-from-laur%C3%A3-n-to-molecular-pathology
#11
REVIEW
Magdalena Cisło, Agata Anna Filip, George Johan Arnold Offerhaus, Bogumiła Ciseł, Karol Rawicz-Pruszyński, Małgorzata Skierucha, Wojciech Piotr Polkowski
In Western countries the majority of gastric cancers (GC) are usually diagnosed in advanced stages reporting a 5-year survival rate of only 26%. The Laurén classification of GC was most widely used in clinical practice since it reflects GC morphology, epidemiology, tumor biology, clinical management and outcome. Despite the initial promise of individualizing antitumor treatment, the management of GC still remains relatively broad and general. Apart from clinical staging, molecular profiling enables targeting of the identified underlying alterations, rather than histology...
April 10, 2018: Oncotarget
https://www.readbyqxmd.com/read/29697008/incorporation-of-p-53-mutation-status-and-ki-67-proliferating-index-in-classifying-her2-neu-positive-gastric-adenocarcinoma
#12
Ayesha Ahmed, Dalal M Al-Tamimi
Her2-neu overexpression has a pathogenetic, therapeutic and a controversial prognostic role in gastric cancer. p-53 mutation status and Ki-67 proliferation index are established prognostic markers in many tumors. In this study we evaluated p-53 and Ki-67 in relation to Her2-neu positive and negative gastric adenocarcinoma (GA). This cross-sectional study was carried out at King Fahd Hospital of Imam Abdulrahman bin Faisal University. Fifty cases of GA were retrieved from pathology archives. Clinico-pathological parameters were evaluated...
December 2018: Libyan Journal of Medicine
https://www.readbyqxmd.com/read/29668600/chilean-gastric-cancer-task-force-a-study-protocol-to-obtain-a-clinical-and-molecular-classification-of-a-cohort-of-gastric-cancer-patients
#13
Gareth I Owen, Mauricio P Pinto, Ignacio N Retamal, María F Fernádez, Betzabe Cisternas, Sebastian Mondaca, Cesar Sanchez, Hector Galindo, Bruno Nervi, Carolina Ibañez, Francisco Acevedo, Jorge Madrid, José Peña, Maria Loreto Bravo, Maria Jose Maturana, Miguel Cordova-Delgado, Diego Romero, Nathaly de la Jara, Javiera Torres, Maria Rodriguez-Fernandez, Manuel Espinoza, Carlos Balmaceda, Matías Freire, Valentina Gárate-Calderón, Fernando Crovari, Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Ariel Zwenger, Ricardo Armisen, Alejandro H Corvalan, Marcelo Garrido
Gastric cancer (GC) is the world's second-leading cause of neoplastic mortality. Genetic alterations, response to treatments, and mortality rates are highly heterogeneous across different regions. Within Latin America, GC is the leading cause of cancer death in Chile, affecting 17.6 per 100,000 people and causing >3000 deaths/y. Clinical outcomes and response to "one size fits all" therapies are highly heterogeneous and thus a better stratification of patients may aid cancer treatment and response...
April 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29553403/potential-impact-of-molecular-classification-on-tailored-lymphadenectomy-for-gastric-cancer
#14
F Roviello, K Polom, A D'Ignazio, V Pascale, D Marrelli
No abstract text is available yet for this article.
March 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29552300/immunoclassification-characterized-by-cd8-and-pd-l1-expression-is-associated-with-the-clinical-outcome-of-gastric-cancer-patients
#15
Weili Wang, Kuansong Wang, Zihua Chen, Ling Chen, Wei Guo, Ping Liao, Daniel Rotroff, Todd C Knepper, Zhaoqian Liu, Wei Zhang, Howard L Mcleod, Yijing He
Background: Gastric cancer (GC) is a major cause of cancer deaths, especially in Eastern Asia. Current classification systems, including the WHO, Lauren, and TCGA, have clarified the pathological and molecular profiles of GC. However, these classifications lack an association with clinical outcome and guidance for medication selection. Objective: We aimed to identify a new immunoclassification for GC to better predict patient prognosis and aid in patient selection for immunotherapy...
February 23, 2018: Oncotarget
https://www.readbyqxmd.com/read/29522457/molecular-characterization-of-gastric-carcinoma-therapeutic-implications-for-biomarkers-and-targets
#16
REVIEW
Lionel Kankeu Fonkoua, Nelson S Yee
Palliative chemotherapy is the mainstay of treatment of advanced gastric carcinoma (GC). Monoclonal antibodies including trastuzumab, ramucirumab, and pembrolizumab have been shown to provide additional benefits. However, the clinical outcomes are often unpredictable and they can vary widely among patients. Currently, no biomarker is available for predicting treatment response in the individual patient except human epidermal growth factor receptor 2 (HER2) amplification and programmed death-ligand 1 (PD-L1) expression for effectiveness of trastuzumab and pembrolizumab, respectively...
March 9, 2018: Biomedicines
https://www.readbyqxmd.com/read/29484116/a-common-molecular-signature-of-intestinal-type-gastric-carcinoma-indicates-processes-related-to-gastric-carcinogenesis
#17
Renata Binato, Everton Cruz Santos, Mariana Boroni, Samia Demachki, Paulo Assumpção, Eliana Abdelhay
Gastric carcinoma (GC) is one of the most aggressive cancers and the second leading cause of cancer death in the world. According to the Lauren classification, this adenocarcinoma is divided into two subtypes, intestinal and diffuse, which differ in their clinical, epidemiological and molecular features. Several studies have attempted to delineate the molecular signature of gastric cancer to develop new and non-invasive screening tests that improve diagnosis and lead to new treatment strategies. However, a consensus signature has not yet been identified for each condition...
January 26, 2018: Oncotarget
https://www.readbyqxmd.com/read/29416011/long-noncoding-rna-pandar-blocks-cdkn1a-gene-transcription-by-competitive-interaction-with-p53-protein-in-gastric-cancer
#18
Jun Liu, Qiwen Ben, Eryi Lu, Xiangyi He, Xiaoqun Yang, Jun Ma, Wen Zhang, Zhiming Wang, Tianshu Liu, Jianjun Zhang, Hongxia Wang
Emerging evidence indicates that lncRNAs play important roles in cancer tumourigenesis and could be used as potential diagnostic biomarkers or therapeutic targets. However, the clinical significance and molecular mechanism of lncRNAs in gastric cancer (GC) is still unclear. The aim of this study was to explore the expression and role of lncRNAs in GC. The relative expression level of lncRNAs in GC samples was examined by an lncRNA microarray analysis, northern blot analysis and qRT-PCR analysis. A Kaplan-Meier survival analysis and univariate and multivariate Cox proportional hazards models were performed to evaluate the clinical and prognostic significance of PANDAR (promoter of CDKN1A antisense DNA damage activated RNA) in GC patients...
February 7, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/29330205/clinical-utility-of-a-stat3-regulated-mirna-200-family-signature-with-prognostic-potential-in-early-gastric-cancer
#19
Liang Yu, Di Wu, Hugh Gao, Jesse J Balic, Anna Tsykin, Tae-Su Han, You Dong Liu, Catherine L Kennedy, Ji Kun Li, Jie Qi Mao, Patrick Tan, Masanobu Oshima, Gregory J Goodall, Brendan J Jenkins
Purpose: The majority of gastric cancer patients are diagnosed with late-stage disease, for which distinct molecular subtypes have been identified that are potentially amenable to targeted therapies. However, there exists no molecular classification system with prognostic power for early-stage gastric cancer (EGC) because the molecular events promoting gastric cancer initiation remain ill-defined. Experimental Design: miRNA microarrays were performed on gastric tissue from the gp130 F/F preclinical EGC mouse model, prior to tumor initiation...
March 15, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29209918/molecular-classification-and-precision-therapy-of-cancer-immune-checkpoint-inhibitors
#20
Yingyan Yu
On May 23, 2017, the US Food and Drug Administration (FDA) approved a treatment for cancer patients with positive microsatellite instability-high (MSI-H) markers or mismatch repair deficient (dMMR) markers. This approach is the first approved tumor treatment using a common biomarker rather than specified tumor locations in the body. FDA previously approved Keytruda for treatment of several types of malignancies, such as metastatic melanoma, metastatic non-small-cell lung cancer, recurrent or metastatic head and neck cancer, refractory Hodgkin lymphoma, and urothelial carcinoma, all of which carry positive programmed death-1/programmed death-ligand 1 biomarkers...
April 2018: Frontiers of Medicine
keyword
keyword
171758
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"